Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1834 | 6173 | 41.8 | 83% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
478 | 3 | PHAGE DISPLAY//CELL FREE PROTEIN SYNTHESIS//ANTIBODY ENGINEERING | 23687 |
1834 | 2 | PHAGE DISPLAY//ANTIBODY ENGINEERING//BISPECIFIC ANTIBODY | 6173 |
2141 | 1 | PHAGE DISPLAY//SCFV//ANTIBODY LIBRARY | 2343 |
8251 | 1 | CANONICAL STRUCTURES//ANTIBODY MODELING//HUMANIZATION | 1275 |
9947 | 1 | BISPECIFIC ANTIBODY//BISPECIFIC ANTIBODIES//CATUMAXOMAB | 1105 |
14481 | 1 | NANOBODY//SINGLE DOMAIN ANTIBODY//VHH | 767 |
18905 | 1 | REPEAT PROTEIN//FN3//ANKYRIN REPEAT | 531 |
31515 | 1 | GANKYRIN//P28GANK//CUEDC2 | 152 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PHAGE DISPLAY | authKW | 619474 | 9% | 22% | 579 |
2 | ANTIBODY ENGINEERING | authKW | 541881 | 4% | 48% | 227 |
3 | BISPECIFIC ANTIBODY | authKW | 499556 | 3% | 55% | 184 |
4 | NANOBODY | authKW | 453293 | 3% | 59% | 155 |
5 | SINGLE DOMAIN ANTIBODY | authKW | 441369 | 2% | 74% | 121 |
6 | SCFV | authKW | 408040 | 4% | 34% | 243 |
7 | SINGLE CHAIN FV | authKW | 290613 | 2% | 47% | 126 |
8 | ANTIBODY LIBRARY | authKW | 277015 | 1% | 68% | 82 |
9 | VHH | authKW | 240609 | 1% | 62% | 78 |
10 | INTRABODY | authKW | 238139 | 1% | 58% | 83 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Biochemistry & Molecular Biology | 17688 | 45% | 0% | 2794 |
2 | Biochemical Research Methods | 12513 | 16% | 0% | 966 |
3 | Immunology | 11469 | 22% | 0% | 1347 |
4 | Biotechnology & Applied Microbiology | 7543 | 16% | 0% | 981 |
5 | Biophysics | 2767 | 9% | 0% | 534 |
6 | Oncology | 1641 | 10% | 0% | 644 |
7 | Medicine, Research & Experimental | 943 | 6% | 0% | 356 |
8 | Cell Biology | 460 | 7% | 0% | 403 |
9 | Virology | 102 | 2% | 0% | 94 |
10 | Mathematical & Computational Biology | 62 | 1% | 0% | 56 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | IG THER Y CO | 49447 | 0% | 100% | 10 |
2 | CHRISTIAN DOPPLER ANTIBODY ENGN | 41877 | 0% | 71% | 12 |
3 | LEHRSTUHL BIOL CHEM | 36655 | 1% | 21% | 35 |
4 | CELLULAIRE MOL IMMUNOL | 28765 | 0% | 73% | 8 |
5 | LARGE MOL | 27129 | 0% | 31% | 18 |
6 | ABT BIOTECHNOL | 25854 | 0% | 35% | 15 |
7 | CLIN COOPERAT GRP BISPECIF ANTIBODIES | 24723 | 0% | 100% | 5 |
8 | PROT ENGN ANTIBODY TECHNOL | 21090 | 0% | 53% | 8 |
9 | GDR2352 | 20601 | 0% | 83% | 5 |
10 | BIOMOLEC ENGN 343 ROYAL PARADE | 19779 | 0% | 100% | 4 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MABS | 87119 | 2% | 15% | 114 |
2 | PROTEIN ENGINEERING DESIGN & SELECTION | 80279 | 2% | 13% | 130 |
3 | PORTLAND PRESS PROCEEDINGS | 74330 | 1% | 40% | 38 |
4 | JOURNAL OF IMMUNOLOGICAL METHODS | 39591 | 5% | 3% | 279 |
5 | MOLECULAR IMMUNOLOGY | 27580 | 3% | 3% | 199 |
6 | PROTEIN ENGINEERING | 25348 | 2% | 5% | 108 |
7 | JOURNAL OF MOLECULAR BIOLOGY | 24139 | 6% | 1% | 340 |
8 | JOURNAL OF MOLECULAR RECOGNITION | 9262 | 1% | 4% | 48 |
9 | HYBRIDOMA | 6521 | 1% | 3% | 53 |
10 | HYBRIDOMA AND HYBRIDOMICS | 5801 | 0% | 7% | 17 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PHAGE DISPLAY | 619474 | 9% | 22% | 579 | Search PHAGE+DISPLAY | Search PHAGE+DISPLAY |
2 | ANTIBODY ENGINEERING | 541881 | 4% | 48% | 227 | Search ANTIBODY+ENGINEERING | Search ANTIBODY+ENGINEERING |
3 | BISPECIFIC ANTIBODY | 499556 | 3% | 55% | 184 | Search BISPECIFIC+ANTIBODY | Search BISPECIFIC+ANTIBODY |
4 | NANOBODY | 453293 | 3% | 59% | 155 | Search NANOBODY | Search NANOBODY |
5 | SINGLE DOMAIN ANTIBODY | 441369 | 2% | 74% | 121 | Search SINGLE+DOMAIN+ANTIBODY | Search SINGLE+DOMAIN+ANTIBODY |
6 | SCFV | 408040 | 4% | 34% | 243 | Search SCFV | Search SCFV |
7 | SINGLE CHAIN FV | 290613 | 2% | 47% | 126 | Search SINGLE+CHAIN+FV | Search SINGLE+CHAIN+FV |
8 | ANTIBODY LIBRARY | 277015 | 1% | 68% | 82 | Search ANTIBODY+LIBRARY | Search ANTIBODY+LIBRARY |
9 | VHH | 240609 | 1% | 62% | 78 | Search VHH | Search VHH |
10 | INTRABODY | 238139 | 1% | 58% | 83 | Search INTRABODY | Search INTRABODY |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | MUYLDERMANS, S , (2013) NANOBODIES: NATURAL SINGLE-DOMAIN ANTIBODIES.ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82. VOL. 82. ISSUE . P. 775-797 | 116 | 79% | 222 |
2 | ROMAO, E , MORALES-YANEZ, F , HU, YZ , CRAUWELS, M , DE PAUW, P , HASSANZADEH, GG , DEVOOGDT, N , ACKAERT, C , VINCKE, C , MUYLDERMANS, S , (2016) IDENTIFICATION OF USEFUL NANOBODIES BY PHAGE DISPLAY OF IMMUNE SINGLE DOMAIN LIBRARIES DERIVED FROM CAMELID HEAVY CHAIN ANTIBODIES.CURRENT PHARMACEUTICAL DESIGN. VOL. 22. ISSUE 43. P. 6500 -6518 | 196 | 66% | 1 |
3 | BRINKMANN, U , KONTERMANN, RE , (2017) THE MAKING OF BISPECIFIC ANTIBODIES.MABS. VOL. 9. ISSUE 2. P. 182 -212 | 176 | 66% | 0 |
4 | STEELAND, S , VANDENBROUCKE, RE , LIBERT, C , (2016) NANOBODIES AS THERAPEUTICS: BIG OPPORTUNITIES FOR SMALL ANTIBODIES.DRUG DISCOVERY TODAY. VOL. 21. ISSUE 7. P. 1076 -1113 | 157 | 52% | 3 |
5 | RAHBARIZADEH, F , AHMADVAND, D , SHARIFZADEH, Z , (2011) NANOBODY; AN OLD CONCEPT AND NEW VEHICLE FOR IMMUNOTARGETING.IMMUNOLOGICAL INVESTIGATIONS. VOL. 40. ISSUE 3. P. 299 -338 | 142 | 68% | 31 |
6 | VAN BOCKSTAELE, F , HOLZ, JB , REVETS, H , (2009) THE DEVELOPMENT OF NANOBODIES FOR THERAPEUTIC APPLICATIONS.CURRENT OPINION IN INVESTIGATIONAL DRUGS. VOL. 10. ISSUE 11. P. 1212 -1224 | 109 | 84% | 72 |
7 | DE MARCO, A , (2011) BIOTECHNOLOGICAL APPLICATIONS OF RECOMBINANT SINGLE-DOMAIN ANTIBODY FRAGMENTS.MICROBIAL CELL FACTORIES. VOL. 10. ISSUE . P. - | 124 | 68% | 49 |
8 | EYER, L , HRUSKA, K , (2012) SINGLE-DOMAIN ANTIBODY FRAGMENTS DERIVED FROM HEAVY-CHAIN ANTIBODIES: A REVIEW.VETERINARNI MEDICINA. VOL. 57. ISSUE 9. P. 439 -513 | 110 | 79% | 20 |
9 | SPIESS, C , ZHAI, QT , CARTER, PJ , (2015) ALTERNATIVE MOLECULAR FORMATS AND THERAPEUTIC APPLICATIONS FOR BISPECIFIC ANTIBODIES.MOLECULAR IMMUNOLOGY. VOL. 67. ISSUE 2. P. 95 -106 | 73 | 66% | 55 |
10 | HOOGENBOOM, HR , (2005) SELECTING AND SCREENING RECOMBINANT ANTIBODY LIBRARIES.NATURE BIOTECHNOLOGY. VOL. 23. ISSUE 9. P. 1105-1116 | 101 | 64% | 502 |
Classes with closest relation at Level 2 |